Burden of disease: assessing quality-of-life impacts in hyperhidrosis

Gabes, Michaela; Donhauser, Theresa; Kann, Gesina; Masur, Clarissa; Apfelbacher, Christian

doi:10.1093/bjd/ljac010

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the impact of HH on quality of life is comparable or even worse than in other major skin diseases, 7,24,25 we chose to assess quality of life as an important patient-reported outcome measure to assess the therapeutic effect of 1% GPB cream. HDSS, HidroQoL© and DLQI demonstrated a significant improvement in the quality of life over the entire study period of 72 weeks compared to baseline assessment.…”

Section: Discussionmentioning

confidence: 99%

“…Studies on the quality of life in patients with and without HH showed that the prevalence of depression and anxiety was significantly higher in patients suffering from HH 6,7 . These findings prove that HH, especially primary axillary HH (PAHH), is not only bothersome but also a serious medical issue for the affected patients and requires appropriate treatment.…”

Section: Introductionmentioning

confidence: 88%

See 1 more Smart Citation

Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial

Szeimies

Abels

Kilić

et al. 2023

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Background Primary axillary hyperhidrosis (PAHH) strongly affects the patient's quality of life. To date, topical treatment options are limited. One percent glycopyrronium bromide (GPB) showed promising efficacy and safety in a pivotal 4‐week Phase 3a study. Objectives To assess efficacy and safety of topical 1% GPB cream in patients with severe PAHH in a long‐term study of 72 weeks versus baseline. Methods This was a long‐term, open‐label, Phase 3b trial for 72 weeks including 518 patients with severe PAHH. Patients were treated with 1% GPB cream once daily for 4 weeks, followed by a flexible dosing scheme (min. twice per week, max. once daily). Primary endpoint was the absolute change in sweat production from baseline to week 12. Further study endpoints included assessment of the severity of PAHH and the impact on quality of life. Results Total median sweat production decreased by 119.30 mg (−65.6%, both median) until week 12. Absolute change in sweat production from baseline to week 12 in logarithmic values was statistically significant (p < 0.0001). Patients' quality of life was improved at all study time points compared to baseline, as assessed by Hyperhidrosis Quality of Life Index and Dermatology Life Quality Index (p < 0.0001). Treatment was safe and locally well‐tolerated with only few mild to moderate adverse drug reactions (ADRs). Dry mouth and application site erythema were the most common reported ADRs. Conclusions Treatment with 1% GPB cream over 72 weeks significantly reduces sweat production and improves quality of life in patients with severe PAHH. One percent GPB cream is well‐tolerated and provides an effective treatment option for long‐term use in patients with severe PAHH.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 88%

Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial

Szeimies

Abels

Kilić

et al. 2023

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

What do Hyperhidrosis Quality of Life Index (HidroQoL©) scores mean? Transferring science into practice by establishing a score banding system

Donhauser,

Gabes,

Özkan

et al. 2023

British Journal of Dermatology

View full text Add to dashboard Cite

Background The Hyperhidrosis Quality of Life Index (HidroQoL ©) is a measure of quality of life (QoL) impacts in hyperhidrosis. Objectives We aimed to establish score banding systems for the HidroQoL total score for specific contexts representing different severity/impact categories by using the Dermatology Life Quality Index (DLQI) and the Hyperhidrosis Disease Severity Scale (HDSS) as anchors, including data from 357 patients from a phase III clinical trial. Methods We used the HDSS, the established DLQI score bands, and two single items (i.e. 5 and 7) of the DLQI as anchors for the creation of banding systems for the HidroQoL. These anchors were chosen via consensus among an expert group according to relevance to patient experience. Due to the distribution of the HDSS and the single DLQI item 7, Receiver Operating Characteristic (ROC) curves were computed, in order to create an optimal cut-off value of the HidroQoL total score. For the DLQI banding system and the single DLQI item 5, we created a banding system for the HidroQoL based on the distribution of their different categories. Results A score of 30 and greater is proposed as cut-off for sweating that “always interferes in daily activities”, based on the HDSS as anchor. In terms of overall skin QoL effects, score bands of 0 – 6, 7 – 18, 19 – 25, 26 – 32, and 33 – 36 represent “no effect”, “small effect”, “moderate effect”, “very large effect” and “extremely large effect” on the patient’s life, respectively. Conclusions In this study, we propose different banding systems for four different contexts: skin-specific QoL (DLQI banding), hyperhidrosis severity (HDSS), working and studying (single DLQI item 7), and social and leisure activities (single DLQI item 5). These banding systems and cut-off values can be used in clinical research and practice to place the patients in different severity categories. ClinicalTrials.gov identifier NCT03658616

show abstract

Epidemiology and health care of hyperhidrosis in Germany: claims data analysis

Hagenström,

Müller,

Ohm

et al. 2024

BMJ Open

View full text Add to dashboard Cite

Background and objectivesData on the population-based epidemiology of hyperhidrosis (HH) are scarce. This study investigated the epidemiology and healthcare of HH in Germany.Design and settingClaims data of adult persons insured by a German statutory health insurance (DAK-Gesundheit) between 2016 and 2020 were analysed. Included were persons aged 18 years and older with a diagnosis of HH (confirmed inpatient or outpatient diagnosis in the observation year) who were continuously insured. Following outcomes were measured: prevalence and incidence rates, severity of hyperhidrosis and inpatient and outpatient care by a group of specialists.ResultsIn 2020, 0.70% of insured adults were confirmed to have HH (mean age 59.5 years, SD 18.9, 61.6% female), with 9.24% having a ‘localised’ form, 8.65% a ‘generalised’ form and 84.80% an ‘unspecified’ form. 0.04% of the total population had a severe form. The incidence was 0.35%. Localised HH was more common in younger age groups (18 to <30 years), while older age groups (70 to <80 years) were significantly more likely to suffer from generalised HH. Systemic anticholinergics were used in 4.55%, and botulinum toxin injection therapy in 0.81%. General practitioners were most frequently involved in care. Inpatient stays due to HH were very rare, with 0.14% in 2019 and 0.04% in 2020.ConclusionMultisource data analysis connecting primary and secondary data will be needed for a complete picture of the healthcare and epidemiology of HH.

show abstract

Burden of disease: assessing quality-of-life impacts in hyperhidrosis

Abstract: With this study it can be concluded that a substantial number of severe axillary HH patients suffers from a tremendous impairment in their QoL. In comparison to other dermatological conditions, the burden of disease in hyperhidrosis is quite high.

Cited by 3 publications

References 7 publications

Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial

Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial

What do Hyperhidrosis Quality of Life Index (HidroQoL©) scores mean? Transferring science into practice by establishing a score banding system

Epidemiology and health care of hyperhidrosis in Germany: claims data analysis

Contact Info

Product

Resources

About